氩氦刀冷冻消融治疗老年早期非小细胞肺癌的临床疗效观察
Clinical study of cryoablation in the treatment of older patients with early stage(I/II)non-small cell lung cancer
邢世江 1李新 1曾维斌 1邓婉芳 1许家健 1黄萍1
作者信息
- 1. 南方医科大学附属小榄医院肿瘤科,广东 中山 528415
- 折叠
摘要
目的:观察氩氦刀冷冻消融治疗老年早期非小细胞肺癌的疗效及安全性。方法:非小细胞肺癌(NSCLC)患者28例,经病理或细胞学确诊,不愿接受手术或无手术适应证的早期(I 期及部分 II 期)的70岁以上老年患者,全部行 CT 引导氩氦刀冷冻消融术,观察局部病灶变化、疗效、并发症及生存情况。结果:术后1个月复查 CT,按实体瘤评价标准缓解率(CR +PR)为71.4%(20/28)。术后3个月及6个月评价疗效(CR+PR)分别为67.9%和64.3%。1~2年随访过程中7例(25.0%)出现转移,其中5例患者出现纵隔淋巴结转移,2例患者出现远处转移,死亡2例,21例(75.0%)患者未见肿瘤复发或转移征象。所有患者均未出现严重并发症。结论:氩氦刀冷冻消融治疗老年早期非小细胞肺癌疗效较好,安全性高,是老年早期 NSCLC 治疗的新选择,具有较好的临床应用前景。
Abstract
Objective:To observe the clinical efficacy and safety of cryoablation in the treatment of older patients with early stage non -small cell lung cancer (NSCLC).Methods:A total of 28 NSCLC older patients(stage I -II) received cryoablation.All patients were followed -up for 12 ~24 months after operation,using contrast -enhanced CT to evaluate the tumor size and enhancement.Results:After 1 month,according to RECIST criteria,the remission rate (CR +PR)was 71.4%.The remission rate after 3 and 6 months was 67.9% and 64.3% respectively.The existence rate in one year was 96.4%.Conclusion:CT -guided percutanous cryoablation may achieve high response rate.It is a simple,safe and reliable procedure for older patients with NSCLC in early stage.It has excellent prospect for clinical applications.
关键词
非小细胞肺癌/氩氦刀冷冻消融/治疗Key words
non -small cell lung cancer (NSCLC)/argon helium cryotherapy/treatment引用本文复制引用
出版年
2016